Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01712490 · OUTCOME

A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma · Source last updated 2026-02-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Baseline up to end of treatment (approximately 1 year)

What was measured

The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.

Analysis population: The safety population included all enrolled participants who received at least 1 dose of any study drug. The safety population-immunogenicity-evaluable participants where baseline and at least one postbaseline sample was available.

Groups in this outcome

A+AVD

Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
A+AVD632

Reported measurements

ATA positive
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
A+AVD109Not reportedNot reportedNot reportedNot reported
nATA positive
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
A+AVD12Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        109
    title
    ATA positive
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        12
    title
    nATA positive
denoms
  1. counts
    1. group Id
      OG000
      value
      632
    units
    Participants
description
The nATA positive was defined as positive ATA with neutralizing activity at any postbaseline visit.
groups
  1. description
    Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\^2), vinblastine 6 mg/m\^2, and dacarbazine 375 mg/m\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.
    id
    OG000
    title
    A+AVD
param Type
NUMBER
population Description
The safety population included all enrolled participants who received at least 1 dose of any study drug. The safety population-immunogenicity-evaluable participants where baseline and at least one postbaseline sample was available.
reporting Status
POSTED
time Frame
Baseline up to end of treatment (approximately 1 year)
title
A+AVD: Number of Participants With Antitherapeutic Antibody (ATA) and Neutralizing Antitherapeutic Antibody (nATA) Positive for Brentuximab Vedotin
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice